- Despite initial clinical responses, a significant number of patients experience relapse. There are two main types of relapses have been reported. The first type linked to poor expansion and durability of CAR-T cells in vivo. The second type linked to the emergence of CD19+ tumor cells.
- CDX is a neoantigen discovered by Chi-Hoon Park, a researcher at the KRICT. CDX is a tetraspanin membrane protein that is highly expressed on normal B cells but downregulated in plasma cells. Hematopoietic stem cells (HSC) do not express CDX. Low expression levels have reported in T cells, macrophages, monocytes, dendritic cells, and natural killer (NK) cells. CDX has not fully elucidated, but it might be linked to survival and apoptotic signals, as well as tumor suppression. High levels of expression have been shown across all types of B-NHL. Therefore, CDX is a potential target for immunotherapy of B-cell malignancies.
- CDX is available for CD19 negative, CD19 resistance, CD19 low expression, and CD19 relapse patients.